Another trastuzumab-based drug conjugate, trastuzumab deruxtecan (DS-8201a or ENHERTU), a conjugate of trastuzumab and a topoisomerase-I inhibitor, deruxtecan, has also been approved for the treatment of breast cancer, including HER2-low breast cancer [227,228]. The gene discussed is ERBB2; the disease is breast cancer.